Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

Arv­inas and Pfiz­er’s tar­get­ed pro­tein de­grad­er has not man­aged to dis­tin­guish it­self from oth­er, sim­i­lar breast can­cer drugs, ac­cord­ing to piv­otal da­ta re­leased Tues­day. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER